18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases

Nuclear Medicine Communications

Volumn 32, Issue 5, 2011, Pages 343-347

  Zissen, Maurice Henry ^a   Kunz, Pamela ^b   Subbarayan, Murugesan ^a   Chin, Frederick T ^a   Conti, Peter S ^c   Fisher, George A ^b   Quon, Andrew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

colorectal cancer; fluorine 18 5 fluorouracil; oncology; positron emission tomography computed tomography

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FLUOROURACIL F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; DIAGNOSTIC AGENT; FLUORINE; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY;

ADENOCARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COLORECTAL METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; METASTASIS; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; COLORECTAL NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 79955025729     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328344894b     Document Type: Article

References (10)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342. (Pubitemid 38702844)
2. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147. (Pubitemid 38524883)
3. Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment. APMIS 2008; 116:695-715.
4. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62. (Pubitemid 40093472)
5. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:3731-3736. (Pubitemid 38697278)
6. Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001; 61:4937-4941. (Pubitemid 32681513)
7. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mühler M, Oberdorfer F, Van Kaick G. Fluorine-1 8-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998; 39:1197-1202. (Pubitemid 28326150)
8. Langenberg MH, Witteveen PO, Lankheet NAG, Roodhart JML, Rosing H, Van den Heuvel IJGM, et al. Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis. Neoplasia 2010; 12:206-213.
9. Baker SD. Pharmacology of fluorinated pyrimidines: eniluracil. Invest New Drugs 2000; 18:373-381.
10. Saleem A, Yap J, Osman S, Brady F, Lucas SV, Jones T, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 2000; 355:2125-2131. (Pubitemid 30364662)